Potent inhibition of hemangiosarcoma development in mice by cidofovir

International Journal of Cancer

Volumn 92, Issue 2, 2001, Pages 161-167

  Liekens, Sandra ^a   Verbeken, Erik ^a   De Clercq, Erik ^a   Neyts, Johan ^b  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Apoptosis; Cidofovir; Hemangiosarcoma; HPMPC; Polyomavirus; Vascular tumor

Indexed keywords

ACYCLIC NUCLEOSIDE; CIDOFOVIR; CYCLINE; CYTARABINE DERIVATIVE; DNA NUCLEOTIDYLEXOTRANSFERASE; GANCICLOVIR; GEMCITABINE; PHOSPHONIC ACID DERIVATIVE;

ANGIOSARCOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOSTASIS; CYTOTOXICITY; DNA VIRUS; HEMANGIOMA; IMMUNOHISTOCHEMISTRY; INOCULATION; MOUSE; NICK END LABELING; NONHUMAN; PAPILLOMA VIRUS; POLYOMA VIRUS; PRIORITY JOURNAL; RAT; RETINITIS; TUMOR GROWTH; TUMOR VOLUME; VASCULAR TUMOR; VIRUS INFECTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BRAIN NEOPLASMS; CELL DIVISION; CELL LINE, TRANSFORMED; CYTOSINE; FEMALE; HEMANGIOSARCOMA; MICE; MICE, NUDE; MICE, SCID; NEOPLASM TRANSPLANTATION; ORGANOPHOSPHORUS COMPOUNDS; PERITONEAL NEOPLASMS; PHOSPHONIC ACIDS; SURVIVAL RATE;

EID: 0035871997     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0215(200102)9999:9999<::AID-IJC1183>3.0.CO;2-K     Document Type: Article

References (45)

1. A novel selective broad-spectrum anti-DNA virus agent
2. Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines
3. Treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome
4. Antiviral drug susceptibility of human herpesvirus 8
5. Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy
6. In search of a selective antiviral chemotherapy
7. A new topical treatment for resistant herpes simplex infections
8. A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS
9. A multicenter phase I/II dose escalation study of single-dose cidofovir gel for treatment of recurrent genital herpes
10. Treatment of adenoviral conjunctivitis with topical cidofovir
11. Prognostic value of JC virus load in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy
12. Successful resolution of progressive multifocal leukoencephalopathy after combination therapy with cidofovir and cytosine arabinoside
13. Response to cidofovir after failure of antiretroviral therapy alone in AIDS-associated progressive multifocal leukoencephalopathy
14. (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): Results of a phase I/II study of a novel antiviral nucleotide analogue
15. Topical cidofovir for severe molluscum contagiosum
16. Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir
17. Treatment of anogenital papillomavirus infections with an acyclic nucleoside phosphonate analogue
18. Cidofovir, a new approach for the treatment of cervix intraepithelial neoplasia grade III (CIN III)
19. Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine]
20. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir
21. The antiviral nucleotide analogs cidofovir and adefovir are novel substrates for human and rat renal organic anion transporter 1
22. Inhibiting effects of cidofovir (HPMPC) on the growth of the human cervical carcinoma (SiHa) xenografts in athymic nude mice
23. The antiviral agent cidofovir [(S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine] has pronounced activity against nasopharyngeal carcinoma grown in nude mice
24. A novel animal model for hemangiomas: Inhibition of hemangioma development by the angiogenesis inhibitor TNP-470
25. Potent inhibition of hemangioma formation in rats by the acyclic nucleoside phosphonate analogue cidofovir
26. Vascular tumors induced by polyoma virus in pregnant rats
27. Topical and intralesional cidofovir: A review of pharmacology and therapeutic effects
28. Metabolic diversity and antiviral activities of acyclic nucleoside phosphonates
29. Mechanism of uptake of the phosphonate analog (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in Vero cells
30. Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells
31. HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: A review of their pharmacology and clinical potential in the treatment of viral infections
32. Control of inducible chemoresistance enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB
33. Ara-C: Cellular and molecular pharmacology
34. Drug-induced apoptosis in lung cancer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway
35. Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells
36. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation
37. Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)-cytosine and 9-(1,3-dihydroxy-2-propoxymethyl)-guanine in the treatment of intracerebral murine cytomegalovirus infections in immunocompetent and immunodeficient mice
38. Antitumor potential of acyclic nucleoside phosphonates
39. Treatment of classical Kaposi's sarcoma with intralesional injections of cidofovir: Report of a case
40. In vitro sensitivity of Kaposi's sarcoma cells to various chemotherapeutic agents including acyclic nucleoside phosphonates
41. J domain-independent regulation of the Rb family by polyomavirus large T antigen
42. Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene
43. Efficiency of binding the retinoblastoma protein correlates with the transforming capacity of the E7 oncoproteins of the human papillomaviruses
44. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
45. Insights into cancer from transgenic mouse models